Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

CEO

Employees

143

Country

ISIN

IL0011552663

Listings

0 Comments

Share your thoughts

FAQ

What is Gamida Cell stock price today?▼

The current price of GMDA is $0.03 USD — it has increased by +0% in the past 24 hours. Watch Gamida Cell stock price performance more closely on the chart.

What is Gamida Cell stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Gamida Cell stocks are traded under the ticker GMDA.

What were Gamida Cell earnings last quarter?▼

GMDA earnings for the last quarter are 0 USD per share, whereas the estimation was -0.14 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Gamida Cell revenue for the last year?▼

Gamida Cell revenue for the last year amounts to 0 USD.

What is Gamida Cell net income for the last year?▼

GMDA net income for the last year is 0 USD.

How many employees does Gamida Cell have?▼

As of April 06, 2026, the company has 143 employees.

In which sector is Gamida Cell located?▼

Gamida Cell operates in the Manufacturing sector.

When did Gamida Cell complete a stock split?▼

Gamida Cell has not had any recent stock splits.